Check if PD-1 plus chemo-radiation helps early nasal lymphoma
Treatments studied
Part of Cancer, Ear, nose & throat, Immune system & allergy clinical trials.
This trial studies whether adding toripalimab (an immune therapy that targets PD-1) to standard chemo-radiation works better for newly diagnosed early-stage nasal natural killer/T-cell lymphoma. It’s designed to see if the combined treatment can improve outcomes while staying safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lymphoma must be proven by biopsy to be nasal (extranodal NK/T-cell lymphoma, nasal type).
- You must be newly diagnosed with stage 1 or stage 2 disease.
- You need at least one measurable or evaluable lesion that doctors can track on scans.
- Your general health should be good enough for study treatment (ECOG performance status 0–2).
- You must be age 18–75, with no other active cancer, and your key organs (heart, liver, kidneys, etc.) must work well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of medications for people with early-stage nasal natural killer/T-cell lymphoma. The goal is to see if adding a targeted therapy to standard treatment helps control the disease with manageable side effects.
This trial tests a new treatment for nasopharyngeal cancer that adds an immune-boosting drug (toripalimab) before and after radiation therapy, while skipping radiation to the neck lymph nodes. It aims to see if this approach is effective and reduces side effects.
This trial studies whether adding an anti–PD-1 immunotherapy to standard chemoradiotherapy can control nasopharyngeal cancer that has come back in the local area. It may help patients live longer or have the cancer respond better compared with chemoradiotherapy alone.
This Phase 3 trial tests whether adding a PD-1 immunotherapy (given with chemotherapy and radiation, and also after) can improve outcomes for people with high-risk nasopharyngeal cancer. It may help by strengthening the immune system’s attack on the cancer alongside standard treatment.
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
This phase 3 trial tests whether adding toripalimab (an immunotherapy medicine) to standard chemo-radiation works better for treating nasopharyngeal cancer that has come back and cannot be removed by surgery. It aims to improve control of the cancer after it returns.
Hear when a new NK/T Cell Lymphoma Nos trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.